您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > LMP744 hydrochloride(MJ-III65 hydrochloride)
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
LMP744 hydrochloride(MJ-III65 hydrochloride)
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
LMP744 hydrochloride(MJ-III65 hydrochloride)图片
CAS NO:308246-57-3
规格:98%
分子量:488.92
包装与价格:
包装价格(元)
1mg电议
5mg电议
10mg电议
20mg电议

产品介绍
LMP744hydrochloride(MJ-III65hydrochloride)是一种DNA嵌和剂,是拓扑异构酶1(Top1)抑制剂,具有抗肿瘤活性。
CAS:308246-57-3
分子式:C24H25ClN2O7
分子量:488.92
纯度:98%
存储:Store at -20°C

Background:

LMP744 hydrochloride (MJ-III65 hydrochloride) is a DNA intercalator and Topoisomerase (Top1) inhibitor with antitumor activity[1].


The GI50 value of LMP744 (MJ-III-65) for NCI60 cells is 0.1 μM[1].LMP744 (0.1-5 μM, 3 days) induces dose-dependent accumulation of cells in the S and G2 phases of the cell cycle[1].|| Cell Cytotoxicity Assay[1]||Cell Line:|P388 and P388 Top1-deficient murine leukemia cells|Concentration:|0.1-100 μM|Incubation Time:|3 days|Result:|induced dose-dependent accumulation of cells in the S and G2 phases of the cell cycle


MJ-III-65 (10-50 mg/kg) administered i.v. push once a week for 4 weeks in nude mice moderately actives against human A253 and FaDu tumor xenografts without significant toxicity[2].|| Animal Model:|Athymic nude mice (nu/nu, female, 20-25 g, 8-12 weeks old) transplanted with A253 and FaDu human head and neck xenografts[2].|Dosage:|10, 25, or 50 mg/kg/week, 4 weeks|Administration:|i.v. push via tail vein|Result:|moderately actived against human A253 and FaDu tumor xenografts without significant toxicity


[1]. Antony S, et al. Bisindenoisoquinoline bis-1,3-{( 5,6-dihydro-5,11-diketo-11H-indeno [1,2-c]isoquinoline)-6-propylamino}propane bis(trifluoroacetate) (NSC 727357), a DNA intercalator and topoisomerase inhibitor with antitumor activity. Mol Pharmacol. 2006 Sep;70(3):1109-20. [2]. Antony S, et al. Cellular topoisomerase I inhibition and antiproliferative activity by MJ-III-65 (NSC 706744), an indenoisoquinoline topoisomerase I poison. Mol Pharmacol. 2005 Feb;67(2):523-30.